Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Core Insights - Verastem Oncology will report its fourth quarter and full year 2025 financial results on March 4, 2026, and will host a conference call to discuss these results and business updates [1][1][1] Company Overview - Verastem Oncology is a biopharmaceutical company focused on developing new medicines for patients with RAS/MAPK pathway-driven cancers [1][1] - The company markets AVMAPKI™ and FAKZYNJA™ CO-PACK in the U.S. and is developing novel small molecule drugs targeting critical signaling pathways in cancer [1][1] Financial Updates - Preliminary, unaudited net product revenues for AVMAPKI™ FAKZYNJA™ CO-PACK for the fourth quarter and full year 2025 were announced, indicating a transformative year for the company [1][1] - The company transitioned to a commercial-stage entity with the launch of AVMAPKI FAKZYNJA [1][1] Strategic Priorities - Verastem Oncology outlined its strategic priorities for 2026, focusing on the clinical development of VS-7375, an oral KRAS G12D inhibitor, in advanced non-small cell lung cancer and other solid tumors [1][1]